🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. Bone marrow mesenchymal stem cells (low dose)

    Sun Yat-sen University

    Acute-On-Chronic Liver Failure

    phase 2 small molecule active

    1 trial

  2. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  3. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  4. CLBS14 (low-dose)

    LISATA THERAPEUTICS, INC.

    Myocardial Ischemia

    phase 2 mab completed

    1 trial

  5. CM-24 and Nivolumab - Dose Escalation

    PURPLE BIOTECH LTD.

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  6. COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab terminated

    1 trial

  7. Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

    Regeneron UK Limited

    Colon Cancer

    phase 2 small molecule active

    1 trial

  8. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  9. Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, LVT-001

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial

  10. Dose 1 of BMN 331

    BioMarin Pharmaceutical Australia Pty Ltd

    Hereditary Angioedema

    phase 2 gene therapy active

    1 trial

  11. Dose A KER-012

    Keros Therapeutics

    Pulmonary Arterial Hypertension

    phase 2 mab completed

    1 trial

  12. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule completed

    1 trial

  13. Dose-attenuated IST and Hetrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sever Aplastic Anaemia

    phase 2 small molecule active

    1 trial

  14. EDP-305 Dose 1

    ENANTA PHARMACEUTICALS INC

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  15. EDP-323 Dose Regimen 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  16. EDP-938 Dose 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  17. Enpatoran low dose

    Serono Europe Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  18. Fixed dose combination Ciprofloxacin/Celecoxib

    NeuroSense Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  19. Full dose preparation

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy Preparation

    phase 2 small molecule completed

    1 trial

  20. GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

    Lacuna Pharma Pty Ltd

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  21. GLPG1837 dose 1

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  22. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  23. GWP42003-P 5 mg/kg/day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  24. HEC585 dose A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources